Acutus Medical has announced a number presentations relating to its mapping and ablation procedures during 26th Annual International AF Symposium (29–31 January, virtual). The studies demonstrate the beneficial capabilities of guided ablation therapy utilising the company’s entire diagnostic and therapeutic suite of EP products, Acutus Medical said in a press release.
In the first of two presentations, Tim Betts, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, will present a persistent atrial fibrillation procedure using both the AcQMap 3D imaging and mapping system and the CE marked AcQBlate FORCE sensing ablation system.
In the second presentation, Dhanunjaya Lakkireddy, Kansas City Heart Rhythm Institute, Kansas, USA will present procedure using Acutus Medical’s AcQMap SuperMap software to facilitate a peer-to-peer discussion on the benefits of a map, ablate, remap strategy when treating complex atrial arrhythmias.
Acutus is also featured in the Early Stage and Emerging New Technologies and Drugs in Cardiac EP I session where Usman Siddiqui, Advent Health, will demonstrate AcQCross Qx, a novel transseptal crossing technology, compatible with multiple sheaths commonly used during electrophysiology procedures.
“AF prevalence is increasing, and effective and efficient treatment is necessary to meet the growing patient demand for ablation procedures. Acutus is focused on developing and advancing technology that makes it easier for physicians to improve outcomes and shorten procedure times,” said Vince Burgess, CEO, Acutus Medical. “The recent commercialisation of our AcQBlate FORCE sensing ablation system in Europe, together with our AcQMap System, has proven what we always believed—a platform that focuses on delivering personalised patient care is exactly what physicians need. Both Prof Betts’ and Dr Lakkireddy’s procedures will highlight the distinct advantages our portfolio delivers.”